TriSalus Life Sciences (TLSIW) Accumulated Expenses (2020 - 2026)

TriSalus Life Sciences has reported Accumulated Expenses for 7 years, with the latest figure at $7.1 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 15.9% year-over-year to $7.1 million; the trailing twelve-month figure through Mar 2026 stood at $7.1 million (down 15.9% YoY), and the FY2025 full-year result was $8.1 million, up 10.07% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $7.1 million, down from $8.1 million in the prior quarter.
• The five-year high for Accumulated Expenses was $11.4 million in Q1 2024, with the low at $6.4 million in Q4 2022.
• Historically, Accumulated Expenses has averaged $8.1 million across 5 years, with a median of $7.6 million in 2024.
• Annual changes were most pronounced in 2023 — Accumulated Expenses soared 65.53% — and 2024, when it plunged 30.32%.
• TriSalus Life Sciences' Accumulated Expenses stood at $6.4 million in 2022, then soared by 65.53% to $10.6 million in 2023, then tumbled by 30.32% to $7.4 million in 2024, then climbed by 10.07% to $8.1 million in 2025, then fell by 12.71% to $7.1 million in 2026.
• The last three Accumulated Expenses figures came in at $7.1 million (Q1 2026), $8.1 million (Q4 2025), and $6.8 million (Q3 2025), per Business Quant data.